REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 81 filers reported holding REATA PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $644,000 | -19.4% | 6,461 | 0.0% | 0.00% | -25.0% |
Q4 2020 | $799,000 | +27.0% | 6,461 | 0.0% | 0.00% | +33.3% |
Q3 2020 | $629,000 | -37.6% | 6,461 | 0.0% | 0.00% | -50.0% |
Q2 2020 | $1,008,000 | +8.0% | 6,461 | 0.0% | 0.01% | -14.3% |
Q1 2020 | $933,000 | -29.4% | 6,461 | 0.0% | 0.01% | 0.0% |
Q4 2019 | $1,321,000 | +154.5% | 6,461 | 0.0% | 0.01% | +133.3% |
Q3 2019 | $519,000 | -14.9% | 6,461 | 0.0% | 0.00% | -25.0% |
Q2 2019 | $610,000 | +10.5% | 6,461 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $552,000 | +52.5% | 6,461 | 0.0% | 0.00% | +33.3% |
Q4 2018 | $362,000 | -31.4% | 6,461 | 0.0% | 0.00% | 0.0% |
Q3 2018 | $528,000 | +133.6% | 6,461 | 0.0% | 0.00% | +50.0% |
Q2 2018 | $226,000 | -11.7% | 6,461 | -48.2% | 0.00% | 0.0% |
Q1 2018 | $256,000 | -27.5% | 12,461 | 0.0% | 0.00% | 0.0% |
Q4 2017 | $353,000 | -9.0% | 12,461 | 0.0% | 0.00% | -33.3% |
Q3 2017 | $388,000 | -1.5% | 12,461 | 0.0% | 0.00% | 0.0% |
Q2 2017 | $394,000 | -0.3% | 12,461 | -28.6% | 0.00% | 0.0% |
Q1 2017 | $395,000 | – | 17,461 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |